1659. Pharmacokinetics/pharmacodynamics of the Novel Gyrase Inhibitor SPR719/SPR720 and Clinical Dose Selection to Treat Pulmonary Mycobacterium avium-complex Disease

BACKGROUND: Current therapy for pulmonary Mycobacterium avium-complex [MAC] disease achieves poor sustained sputum conversion rates and is poorly tolerated. SPR719, the active metabolite of SPR720, a novel gyrase inhibitor, has demonstrated low MICs against MAC. SPR720 is being developed as an oral...

Descripción completa

Detalles Bibliográficos
Autores principales: Deshpande, Devyani, Kuret, Daniel, Cirrincione, Kayle, Cotroneo, Nicole, Melnick, David, Lister, Troy, Stokes, Suzanne, Gumbo, Tawanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777696/
http://dx.doi.org/10.1093/ofid/ofaa439.1837

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777696/
http://dx.doi.org/10.1093/ofid/ofaa439.1837

Ejemplares similares